Phenprocoumon
Showing 1 - 25 of 53
Rivaroxaban Versus Low-molecular-weight Heparin and
Completed
- Venous Thromboembolism
- Rivaroxaban (Xarelto, BAY 59-7939)
- LMWH and Phenprocoumon
-
Multiple Locations, GermanyMultiple facilities
Apr 27, 2022
Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral
Completed
- Atrial Fibrillation
- Phenprocoumon
- +3 more
-
Multiple Locations, GermanyMany Locations
Nov 24, 2020
Atrial Fibrillation, End-stage Kidney Disease Trial in Münster (Apixaban, Phenprocoumon)
Recruiting
- Atrial Fibrillation
- End-stage Kidney Disease
- Apixaban
- Phenprocoumon
-
Münster, GermanyUniversitätsklinikum Münster
Apr 26, 2021
Acute Coronary Syndrome, Atrial Fibrillation, Coronary Artery Disease Trial in Germany (Dual Therapy, Triple Therapy)
Completed
- Acute Coronary Syndrome
- +2 more
- Dual Therapy
- Triple Therapy
-
Munich, Bavaria, Germany
- +15 more
Aug 12, 2020
Anticoagulants and Bleeding Disorders Trial in Rüdersdorf (Venous and Fingerstick blood draws, Venous blood draw)
Completed
- Anticoagulants and Bleeding Disorders
- Venous and Fingerstick blood draws
- Venous blood draw
-
Rüdersdorf, GermanyCLINICAL SITE Klinik am See, Rehabilitation Clinic for Cardiovas
Feb 19, 2020
REVIparin-BRIDging-in a General Practice Setting in GErmany
Terminated
- Thromboembolism
-
Berlin, Germany
- +10 more
Mar 17, 2022
Antiphospholipid Syndrome, Arterial Thrombosis Trial in Buenos Aires, Córdoba, Hamilton (Dual antiplatelet therapy, Combined
Recruiting
- Antiphospholipid Syndrome
- Arterial Thrombosis
- Dual antiplatelet therapy
- +3 more
-
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
- +2 more
Dec 12, 2022
Atrial Fibrillation Trial in Germany (CE-mark approved LAA closure devices, Acetylsalicylic acid, Clopidogrel)
Recruiting
- Atrial Fibrillation
- CE-mark approved LAA closure devices
- +8 more
-
Berlin, Germany
- +25 more
Jul 29, 2021
Cervical Artery Dissection Trial in Denmark, Germany, Switzerland (Acetylsalicylic acid, Vitamin K antagonist)
Completed
- Cervical Artery Dissection
- Acetylsalicylic acid
- Vitamin K antagonist
-
Copenhagen, Denmark
- +9 more
Jan 14, 2020
Potential Adverse Outcomes in Routine Clinical Practice
Completed
- Venous Thrombosis
- +3 more
- Rivaroxaban (Xarelto, Bay59-7939)
- Standard of care
-
Multiple Locations, Germany(unnamed)
Oct 21, 2021
Atrial Fibrillation or Atrial Flutter, Thrombosis of Left Atrial Appendage Trial in Germany (Dabigatran etexilate,
Terminated
- Atrial Fibrillation or Atrial Flutter
- Thrombosis of Left Atrial Appendage
- Dabigatran etexilate
- Phenprocoumon
-
Bad Krozingen, Germany
- +13 more
Jul 24, 2019
Left Ventricular Assist Device Patients
Completed
- End-stage Heart Failure
- +2 more
- VerifyNow antiplatelet therapy response test
-
Vienna, AustriaMedical University of Vienna
Nov 28, 2023
Atrial Fibrillation or Pulmonary Embolism, Need of Long Term Oral Anticoagulation Therapy (OAT), Existent Coronary or Valvular
Completed
- Atrial Fibrillation or Pulmonary Embolism
- +2 more
- Rivaroxaban or Marcumar
-
Coburg, Bavaria, Germany
- +2 more
Oct 21, 2020
Chronic Lymphocytic Leukemia Trial in Milano (Venetoclax, Imbruvica Oral Product)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Venetoclax
- Imbruvica Oral Product
-
Milano, MI, ItalyOspedale San Raffaele
Apr 2, 2022
Patients Treated With Dabigatran or VKA for Stroke Prevention in
Completed
- Atrial Fibrillation
- Dabigatran etexilate
- Vitamin K antagonists
-
Multiple Locations, Germany(unnamed)
Apr 18, 2019
Registration of Idarucizumab for IntraCranial Hemorrhage
Completed
- Intracranial Hemorrhage
- Dabigatran Etexilate Oral Capsule [Pradaxa]
- +2 more
-
Bad Aibling, Germany
- +32 more
Apr 6, 2022
Aortic Valve Disease, Aortic Valve Stenosis, Stroke Trial in Nieuwegein (Continuation of oral anticoagulants, Interruption of
Recruiting
- Aortic Valve Disease
- +6 more
- Continuation of oral anticoagulants
- Interruption of oral anticoagulants
-
Nieuwegein, Utrecht, NetherlandsSt. Antonius Ziekenhuis
Feb 8, 2022
Adverse Drug Reaction Trial in Worldwide (Pharmacogenomic testing)
Completed
- Adverse Drug Reaction
- Pharmacogenomic testing
-
Vienna, Austria
- +6 more
Apr 15, 2022
Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
Completed
- Acute Coronary Syndrome
- +3 more
- Rivaroxaban (Xarelto, BAY59-7939)
- Standard of care drugs
-
Multiple Locations, SwedenMany Locations
Sep 22, 2021
Potential Adverse Outcomes in Routine Clinical Pratice
Completed
- Venous Thrombosis
- +3 more
- Rivaroxoban (Xarelto, Bay59-7939)
- Standard of care
-
Multiple Locations, Netherlands(unnamed)
Sep 22, 2021
Developing Anticoagulation Self-Report Measure in Adults
Not yet recruiting
- Adults Undergoing Oral Anticoagulation Therapy
- Participation in an web-based survey
-
San Donato Milanese, Milano, ItalyIRCCS Policlinico San Donato
Jul 26, 2023
Unsuspected Pulmonary Embolism in Cancer Patients
Completed
- Unsuspected Pulmonary Embolism
- Heparin, fondaparinux, vitamin-K antagonists, aspirin
-
Washington, District of Columbia
- +45 more
Aug 7, 2019
Plasma Transfusion in Major Vascular Surgery
Completed
- Aortic Aneurysm, Abdominal
- Arterial Occlusive Diseases
- Plasma transfusion
-
Slagelse, Region Zealand, DenmarkSlagelse Hospital
Jan 25, 2021
Atrial Fibrillation Trial in Worldwide (Edoxaban, VKA-Based Regimen)
Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k
Completed
- Atrial Fibrillation
- Rivaroxaban (Xarelto, BAY597939)
- Phenprocoumon (branded and generics)
-
Multiple Locations, Germany(unnamed)
Dec 22, 2017